NCT lookup

Inclusion Criteria:

* Age ≥18 years at the time of screening.
* Be able and willing to sign the informed consent form (ICF).
* Patients with histologically or cytologically documented, muscle invasive urothelial carcinoma (ie, T2 toT4, any N, any M) of bladder (see National Comprehensive Cancer Network \[NCCN\] Bladder Cancer Guidelines), who had not been previously treated with any systemic chemotherapy, radiotherapy, investigational product, or biologic therapy for cancer treatment.
* For PD-L1 testing by IHC assay, all patients were able to provide a newly acquired tumor sample within 60 days before enrollment by cystectomy, transurethral resection or biopsy. Samples with limited tumor content and fine needle aspirate specimens were not acceptable. Specimens from metastatic bone lesions were typically unacceptable unless there was a significant soft tissue component. The tumor specimen submitted to establish PD-L1 status should be of sufficient quantity to allow for PD-L1 IHC analyses and was preferred in FFPE blocks.

Exclusion Criteria:

* Prior acquiring tumor tissue samples exposure to immune-mediated therapy (including Bacillus Calmette Guerin), including but not limited to, any anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti PD L2 antibodies, therapeutic anticancer vaccines.
* Any concurrent chemotherapy, investigational product, or biologic therapy for cancer treatment. Note: Local treatment of isolated lesions, excluding target lesions, for palliative intent was acceptable (eg, local surgery or radiotherapy).

• Beijing, China
• Beijing, China
• Changchun, China
• Changsha, China
• Chengdu, China
• Guangzhou, China
• Guangzhou, China
• Hangzhou, China
• Jinan, China
• Meizhou, China
• Nanjing, China
• Shanghai, China
• Shanghai, China
• Shenyang, China
• Wuhan, China
• Xiamen, China
• Zhengzhou, China